๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers

โœ Scribed by Dooley, K E; Bliven-Sizemore, E E; Weiner, M; Lu, Y; Nuermberger, E L; Hubbard, W C; Fuchs, E J; Melia, M T; Burman, W J; Dorman, S E

Book ID
115458922
Publisher
Nature Publishing Group
Year
2012
Tongue
English
Weight
637 KB
Volume
91
Category
Article
ISSN
0009-9236

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics and safety of binodenos
Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers
โœ Richard J. Barrett; Michael J. Lamson; James Johnson; William B. Smith ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› Springer ๐ŸŒ English โš– 181 KB

## Background: Binodenoson, a highly selective agonist of the adenosine a 2a receptor, is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging. this study was designed to assess the single-dose pharmacokinetics, safety, and tolera

The single dose pharmacokinetics and saf
The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers
โœ Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarp ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 201 KB ๐Ÿ‘ 2 views

The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg